Supraspinal anti-allodynic and rewarding effects of endomorphins in rats.
Two potent endogenous opioid peptides, endomorphin-1 (EM-1) and -2 (EM-2), which are selective micro-opioid agonists, have been identified from bovine and human brain. These endomorphins were demonstrated to produce a potent anti-allodynic effect at spinal level. In the present study, we further investigated their supraspinal anti-allodynic effects and rewarding effects. In a neuropathic pain model (sciatic nerve crush in rats), EM-1 and -2 (15 microg, i.c.v.) both showed significant suppressive effects in the cold-water allodynia test, but EM-1 showed a longer duration than EM-2. Naltrexone (NTX; 15 microg) and naloxonazine (NLZ; 15 microg) were both able to completely block the anti-allodynic effects of EM-1 and -2. In the tests of conditioned place preference (CPP), only EM-2 at the dose of 30 microg showed significant positive rewarding effect, whereas both endomorphins did not induce any reward at the dose of 15 microg. Due to the low solubility and the undesired effect (barrel rotation of the body trunk), EM-1 was not tested for the dose of 30 microg in the CPP tests. It was also found that acute EM-2 (30 microg) administration increased dopamine turnover in the shell of nucleus accumbens in the microdialysis experiments. From these results, it may suggest that EM-1 and -2 could be better supraspinal anti-allodynic agents compared with the other opioid drugs, although they may also induce rewarding.
Huang
Eagle Yi-Kung
EY
Department of Pharmacology, National Defense Medical Center 161, Min-Chuan East Road, Sec. 6, Nei-Hu, Taipei 114, Taiwan, ROC.
Chen
Ching-Ming
CM
Tao
Pao-Luh
PL
D000701:Analgesics, Opioid; D000818:Animals; D008297:Male; D009270:Naloxone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009271:Naltrexone / Q000008:administration & dosage; D009292:Narcotic Antagonists; D009408:Nerve Compression Syndromes; D009842:Oligopeptides / Q000008:administration & dosage*; D010146:Pain / Q000209:etiology; D059408:Pain Management; D010147:Pain Measurement; D051381:Rats; D017207:Rats, Sprague-Dawley
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D009842:Oligopeptides; C105293:endomorphin 1; D009270:Naloxone; C105294:endomorphin 2; D009271:Naltrexone; C034643:naloxonazine